Abstract
Aim:
To study the effects of LY294002, an inhibitor of class I phosphatidylinositol 3-kinase (PI3K), on proliferation and apoptosis of SGC7901 gastric cancer cells.
Methods:
The MTT assay was used to determine the cytotoxic effects of LY294002. Cell cycle distribution was analyzed using flow cytometry and apoptosis was assessed using flow cytometry analysis after staining DNA with propidium iodide. Mitochondrial membrane potential was measured using the fluorescent probe JC-1. Expression of p53 and PUMA was determined using real-time RT-PCR and Western blotting analysis.
Results:
The viability of SGC7901 cells was significantly reduced by LY294002 treatment. Expression of p53 and PUMA was induced, and mitochondrial membrane potential collapsed after treatment with LY294002. LY294002 induced apoptotic cell death.
Conclusion:
Activation of the p53 pathway is involved in LY294002-induced SGC7901 cell death.
Similar content being viewed by others
Article PDF
References
Parkin DM, Bray FI, Devesa SS . Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37: S4–6.
Jemal A, Thomas A, Murray T, Thun M . Cancer statistics. CA Cancer J Clin 2002; 52: 23–47.
Zheng L, Wang L, Ajani J, Xie K . Molecular basis of gastric cancer development and progression. Gastric Cancer 2004; 7: 61–77.
Vogt PK . PI3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med 2001; 7: 482–4.
Oldham S, Hafen E . Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol 2003; 13: 79–85.
Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003; 63: 2742–6.
Neve RM, Holbro T, Hynes NE . Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002; 21: 4567–76.
Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, White-head RH, et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001; 61: 7426–79.
Toker A, Cantley LC . Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997; 387: 673–6.
Ullrich A, Schlessinger J . Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203–12.
Franke TF, Kaplan DR, Cantley LC . PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88: 435–7.
Carpenter CL, Cantley LC . Phosphoinositide kinases. Biochemistry 1990; 29: 11147–56.
Vanhaesebroeck B, Waterfield MD . Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253: 239–54.
Hawkins PT, Anderson KE, Davidson K, Stephens LR . Signalling through class I PI3Ks in mammalian cells. Biochem Soc Trans 2006; 34: 647–62.
Maehama T, Dixon JE . PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999; 9: 125–8.
Shayesteh L, Lu Y, Kuo W, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99–102.
Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR . Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 2002; 22: 965–77.
Vivanco I, Sawyers CL . The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489–501.
Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, et al. PI3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005; 11: 507–14.
Oren M . Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10: 431–42.
Vousden KH, Lu X . Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594–604.
Vlahos CJ, Matter WF, Hui KY, Brown RF . A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-1 (LY294002). J Biol Chem 1994; 269: 5241–8.
Alvarez-Tejado M, Naranjo-Suarez S, Jiménez C, Carrera AC, Landázuri MO, del Peso L . Hypoxia induced the activation of the phosphatidy-linositol 3-kinase/Akt cell survival pathway in PC12 cells. J Biol Chem 2001; 276: 22368–74.
Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE, et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha, 25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2001; 15: 1860–72.
Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733–7.
Semba S, Itoh N, Ito M, Harada M, Yamakawa M . The in vitro and in vivo effects of 2 -(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res 2002; 8: 1957–63.
Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M . Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002; 94: 3127–34.
Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB . In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6: 880–6.
Moll UM, Zaika A . Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 2001; 493: 65–9.
Erster S, Mihara M, Kim RH, Petrenko O, Moll UM . In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004; 24: 6728–41.
Crighton D, Ryan KM . Splicing DNA-damage responses to tumour cell death. Biochim Biophys Acta 2004; 1705: 3–15.
Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B . PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673–82.
Nakano K, Vousden KH . PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683–94.
Yu J, Zhang L . No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 2003; 4: 248–9.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Project supported by the Health Fund of Jiangsu Province (H200719); Suzhou Social Development Fund (SS0517) and Jiangsu Six Talant Project (R2317344).
Rights and permissions
About this article
Cite this article
Xing, Cg., Zhu, Bs., Liu, Hh. et al. LY294002 induces p53-dependent apoptosis of SGC7901 gastric cancer cells. Acta Pharmacol Sin 29, 489–498 (2008). https://doi.org/10.1111/j.1745-7254.2008.00770.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00770.x
Keywords
This article is cited by
-
Exploring the potential of chromone scaffold compounds in cancer therapy: targeting key kinase pathways
Medicinal Chemistry Research (2023)
-
Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells
Molecular Biology Reports (2014)
-
Hydrocarbon accumulation principles in troughs within faulted depressions and their significance in exploration
Petroleum Science (2011)
-
Modulation of cancer cell proliferation by cell survival signal Akt and tumor suppressive energy sensor AMP-activated protein kinase in colon cancer cells treated with resveratrol
Food Science and Biotechnology (2010)